[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"abdulmajeed hammadi\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100543256","bone-marrow-aspirate-concentrate-for-anterior-cruciate-ligament-tear-treatment-100543256",false,"NCT06353503","Bone Marrow Aspirate Concentrate for Anterior Cruciate Ligament Tear Treatment.","Using Autologous Bone Marrow Aspirate Concentrate to Treat Complete Anterior Cruciate Ligament Tear.","Inclusion Criteria:\n\n1- Confirmed diagnosis of complete or partial ACL tear via clinical examination and imaging studies.\n\n2\\. Aged between 20 and 55 years, to encompass the typical age range of patients with sports-related ACL injuries.\n\nExclusion Criteria:\n\n1- Patients with a history of bleeding disorders, as this could complicate the aspiration and injection procedures.\n\n2\\. Individuals with a history of malignancy, due to the potential risks associated with growth factors present in BMAC.\n\n3\\. Critically ill patients or those with comorbidities","ALL","20 Years","55 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","A single armed multicenter study enrolling 20 patients using autologous bone marrow aspirate concentrate (which is done under local or general anesthesia to aspirate around 1-2 cc\u002Fkg body weight then concentration which is done by using centrifugation and special disposable kit) local injection of 4 cc per joint under ultrasonic guidance ,completely sterile field with local anesthesia.",[27],"Anterior Cruciate Ligament Tear","RECRUITING","2025-08-02",{"date":31,"type":32},"2025-08-07","ACTUAL",{"date":34,"type":32},"2024-04-02",{"date":36,"type":21},"2026-09-27",{"name":38,"class":39},"abdulmajeed hammadi","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100539338","treatment-of-premature-ovarian-insufficiency-using-bone-marrow-cells-100539338","NCT06302543","Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells","Treatment of Premature Ovarian Insufficiency Using Autologous Bone Marrow Concentrates Through Transvaginal Approach Under Ultrasound Guidance","alfarah","Inclusion Criteria:\n\n1. clinical diagnosis of premature Ovarian insufficiency.\n2. ineffective hormonal therapy.\n3. biochemical evidence of high gonadotropins.\n\nExclusion criteria:\n\n1. solid or hematological malignancies.\n2. bleeding disorders.\n3. rejection of the procedure.",true,"FEMALE","30 Years","60 Years",{"count":54,"type":21},10,[24],"investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under ultrasound guidance with experienced gynecologist and to look for the results including: laboratory evidence through hormonal study ultrasound proof of ovarian follicle development. premature ovarian insufficiency is characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotropin hormones and low estrogen and anti-Mullerian hormone.\n\nAutologous use of stem cells from bone marrow are alternative safe minimal manipulative products that can provide a solution to this clinical problem without the need for oocyte donation program.",[58],"Premature Ovarian Insufficiency",[60],"premature ovarian failure,bone marrow,treatment",{"date":62,"type":32},"2025-08-05",{"date":64,"type":32},"2024-03-01",{"date":66,"type":21},"2026-03-10",{"name":38,"class":39},""]